ArticleSmall (Weinheim an der Bergstrasse, Germany)2019
Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy.
Article in Small (Weinheim an der Bergstrasse, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 90 citations in OpenAlex.
- Aptamer-Directed Porous DNA Nanocomposite Hydrogel for Active Pulp Preservation: Immunomodulation, Stem Cell Recruitment and Reparative Dentinogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- A triple combination strategy for nasopharyngeal carcinoma: Aptamer-guided liposomal chemotherapy, engineered NK cells, and Fc-enhanced PD-L1 antibody therapy.Acta pharmaceutica Sinica. B · 2026Article
- From Selection to Use: Aptamers as Targeting Reagents in Hematology.Biomedicines · 2026Review
- Amphiphilic Lipid-Single-Stranded DNA Conjugate-Mediated Cell Surface Engineering for Programmable Intercellular Tethering and Immune Synapse Formation.Biomaterials research · 2026Article
- Multivalent aptamer engineered and functionalized NK cells for enhanced adoptive immunotherapy in CD30-positive malignant lymphoma.Molecular therapy. Nucleic acids · 2025Article
- CAR19-T/NK cell and circular aptamer-drug conjugate (ApDC) combination treatment increases immunotherapy efficacy.Molecular and cellular biochemistry · 2025Article
- Natural killer cell membrane manipulation for augmented immune synapse and anticancer efficacy.Materials today. Bio · 2025Review
- Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer Therapy.International journal of molecular sciences · 2025Review
- Bioengineered therapeutic systems for improving antitumor immunity.National science review · 2025Review
- Development of Natural Killer Cell-Drug Conjugates via Membrane-Installed Liposomes for Pancreatic Cancer Treatment.Biomaterials research · 2025Article
- Research Progress of NK Cells in Glioblastoma Treatment.OncoTargets and therapy · 2025Review
- Aptamer based immunotherapy: a potential solid tumor therapeutic.Frontiers in immunology · 2025Review
- Antibody-targeted T cells and natural killer cells for cancer immunotherapy.Journal of nanobiotechnology · 2024Article
- Natural Killer-Based Therapy: A Prospective Thought for Cancer Treatment Related to Diversified Drug Delivery Pathways.Pharmaceutics · 2024Review
- Networked Cluster Formation via Trigonal Lipid Modules for Augmented Ex Vivo NK Cell Priming.International journal of molecular sciences · 2024Article
- Artificially Modified NK Cell-Based Synergistic Immuno-Gene-Photodynamic Therapy for Cancer.International journal of nanomedicine · 2024Article
- Breast cancer immunotherapy: a comprehensive review.Clinical and experimental medicine · 2023Review
- Research progress on pathogenic and therapeutic mechanisms of Enterovirus A71.Archives of virology · 2023Review
- Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma.Discover oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Natural killer (NK) cells are a key component of the innate immune system as they can attack cancer cells without prior sensitization. However, due to lack of cell-specific receptors, NK cells are not innately able to perform targeted cancer immunotherapy. Aptamers are short single-stranded oligonucleotides that specifically recognize their targets with high affinity in a similar manner to antibodies. To render NK cells with target-specificity, synthetic CD30-specific aptamers are anchored on cell surfaces to produce aptamer-engineered NK cells (ApEn-NK) without genetic alteration or cell damage. Under surface-anchored aptamer guidance, ApEn-NK specifically bind to CD30-expressing lymphoma cells but do not react to off-target cells. The resulting specific cell binding of ApEn-NK triggers higher apoptosis/death rates of lymphoma cells compared to parental NK cells. Additionally, experiments with primary human NK cells demonstrate the potential of ApEn-NK to specifically target and kill lymphoma cells, thus presenting a potential new approach for targeted immunotherapy by NK cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.